Cancer involving the omentum rarely starts there, and that distinction shapes nearly everything about survival. In most cases, “omentum cancer” means cancer that has spread to the omentum from a nearby organ, most commonly the ovaries, peritoneum, or stomach. Because the type and origin of the cancer vary so widely, five-year survival rates range from under 20% for aggressive metastatic disease to above 40% when the right combination of surgery and chemotherapy is possible. Understanding which kind of omental involvement you or someone you know is dealing with is the first step toward interpreting any survival figure.
Why the Omentum Is Usually a Destination, Not an Origin
The omentum is a large, fatty apron of tissue that drapes over the intestines inside the abdomen. It has a rich blood supply and is packed with immune cells, which makes it both a surveillance organ and, unfortunately, a welcoming environment for cancer cells that break free from tumors elsewhere. Ovarian cancer, gastric cancer, and colorectal cancer all have a strong tendency to seed the omentum as they advance. When imaging or surgery reveals tumor masses studding the omentum, the clinical term is often “omental cake,” a thick, matted layer of cancer replacing the normal fatty tissue. The presence of omental cake has long been recognized as a marker of worse outcomes in advanced ovarian cancer because it signals widespread abdominal disease and makes complete surgical removal harder.
1PubMed Central. The Influence of “Omental Cake” Presence on the Completeness of Cytoreduction in Advanced-stage Ovarian CancerTrue primary cancers of the omentum are exceedingly rare. The two main types are primary peritoneal carcinoma, which behaves much like ovarian cancer but arises from the lining of the abdominal cavity, and malignant peritoneal mesothelioma, which is linked to asbestos exposure and develops in the mesothelial cells covering the peritoneum and omentum. Each carries its own survival profile.
Survival in Primary Peritoneal Carcinoma
Primary peritoneal carcinoma (PPC) accounts for a small fraction of abdominal cancers, but it can be just as aggressive as advanced ovarian cancer. A large analysis of over 2,500 patients from the U.S. SEER database found a mortality rate of roughly 73%, with mean survival of about 43 months. Survival times ranged enormously, from under a month to more than 20 years, highlighting how much individual factors matter.
2Journal of Clinical Oncology. An overview of survival and demographic disparities in primary peritoneal carcinoma: Insights from Surveillance, Epidemiology, and End-Results (SEER) database (2000 to 2021)Smaller studies paint a somewhat grimmer picture. One Korean series reported a median overall survival of about 23 months and an estimated three-year survival rate of 29%. In that study, the patient’s physical condition at diagnosis was the strongest predictor of how long they lived, and there was a trend suggesting that optimal surgical removal of tumor tissue also helped.
3Cancer Research and Treatment. Clinical Characteristics of Primary Peritoneal CarcinomaA Chinese study of advanced PPC found a median survival of 42 months overall, but that number hid dramatic variation. Patients with the most common subtype (primary peritoneal serous papillary carcinoma) had a median survival of 44 months, while those with rarer, more aggressive subtypes survived a median of only 13 to 19 months. The chemotherapy regimen also mattered: patients given a taxane-platinum combination survived a median of 75 months compared with 28 months for those on an older regimen.
4PubMed Central. Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analysesSurvival in Malignant Peritoneal Mesothelioma
Malignant peritoneal mesothelioma (MPM) is another cancer that can involve the omentum directly. It is rare and historically carried a dismal prognosis, but outcomes have improved significantly with the combination of aggressive surgery and heated intraperitoneal chemotherapy (HIPEC). A multi-institutional study of 405 patients who received this combined approach reported a median survival of 53 months and a five-year survival rate of 47%.
5PubMed Central. Peritoneal mesotheliomaThose numbers apply to patients who were selected for aggressive treatment. Looking more broadly, a national analysis found that overall survival for peritoneal mesothelioma improved over time, from a median of 15 months in the early 1990s to 38 months by the late 2000s, likely reflecting both better patient selection and advances in surgical technique.
5PubMed Central. Peritoneal mesotheliomaWhere you receive treatment makes a measurable difference. A study comparing academic medical centers to community hospitals found that five-year survival for peritoneal mesothelioma was about 30% at academic centers versus roughly 18% at community facilities. Treatment at a community hospital was independently associated with a higher risk of death even after adjusting for other factors.
6Journal of Gastrointestinal Surgery. Survival Outcomes for Malignant Peritoneal Mesothelioma at Academic Versus Community HospitalsOne encouraging pattern is that for patients who survive the first year or two, the outlook continues to improve. An analysis of over 1,500 MPM patients found that conditional survival rates rose with each year survived after diagnosis, though this improvement eventually leveled off.
7PubMed Central. Conditional survival patterns and individualized prognostic prediction in malignant peritoneal mesotheliomaWhen Ovarian Cancer Spreads to the Omentum
The most common reason a person hears the words “omentum” and “cancer” together is ovarian cancer. Advanced ovarian cancer frequently seeds the omentum, and when it does, the prognosis worsens substantially. A study comparing ovarian cancer patients with and without omental spread found five-year overall survival rates of about 43% in the group with omental metastasis versus 94% in the group without it. Omental involvement also made recurrent disease harder to treat: response rates to chemotherapy for recurrence were about 32% in the omental-metastasis group compared with 86% in the group without omental spread.
8PubMed Central. Omental metastasis as a predictive risk factor for unfavorable prognosis in patients with stage III–IV epithelial ovarian cancerThese numbers underscore why omental metastasis is treated as a strong independent risk factor. Even after accounting for other variables, the hazard ratio for death was nearly nine times higher in patients whose cancer had reached the omentum.
8PubMed Central. Omental metastasis as a predictive risk factor for unfavorable prognosis in patients with stage III–IV epithelial ovarian cancerThe Role of Surgical Completeness
Across nearly every type of cancer involving the omentum, how much tumor the surgeon can remove is one of the most powerful predictors of survival. In advanced ovarian cancer, patients who had all visible tumor removed during surgery survived a median of 86 months. When small residual disease remained (under 1 cm), median survival dropped to 46 months. With larger residual masses, it fell further to 37 months.
9PubMed. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancerFor ovarian cancer specifically, omentectomy (removing the omentum itself) is a standard part of staging and debulking surgery. A large database study of over 13,000 patients with stage I through IIIA ovarian cancer found that roughly half underwent omentectomy during primary surgery. The procedure provided only about a 3% absolute improvement in cancer-specific survival, and after careful statistical adjustment, it did not show a clear benefit in these earlier-stage patients.
10PubMed Central. The impact of omentectomy on cause-specific survival of Stage I–IIIA epithelial ovarian cancer: A PSM–IPTW analysis based on the SEER databaseThat finding might sound contradictory, but the key is staging. In early-stage disease where the omentum does not yet harbor visible cancer, removing it may not add much. In advanced disease where the omentum is riddled with tumor, removing it is part of the broader goal of eliminating all visible disease, and that broader goal clearly improves survival.
Omentectomy in Gastric Cancer
The omentum also factors into surgical decisions for stomach cancer. Traditionally, surgeons removed the entire omentum during gastrectomy for advanced gastric cancer, on the theory that it might harbor microscopic disease. More recent evidence has questioned whether total omentectomy is necessary. A meta-analysis found that partial omentectomy was actually associated with slightly better overall survival than total omentectomy, along with shorter operating times and less blood loss, with no difference in complication rates or disease-free survival.
11PubMed Central. Partial Versus Total Omentectomy in Patients with Gastric Cancer: A Systemic Review and Meta-AnalysisA separate propensity-matched comparison confirmed these findings, showing no significant difference in disease-free or disease-specific survival between total and partial omentectomy groups.
12PubMed Central. A comparison of total versus partial omentectomy for advanced gastric cancer in laparoscopic gastrectomyA study looking at long-term outcomes after omentum-preserving versus omentum-resecting gastrectomy found identical three-year overall survival rates of about 79% in both groups, with no difference in recurrence-free survival or the rate of peritoneal recurrence.
13Scientific Reports. Long-term outcomes of omentum-preserving versus resecting gastrectomy for locally advanced gastric cancer with propensity score analysisThese results are shifting surgical practice toward less radical omentum removal in gastric cancer, which reduces operative burden without apparently sacrificing cancer outcomes.
HIPEC and Its Impact on Survival
For cancers that have spread across the peritoneal surfaces, including the omentum, one of the most significant treatment advances has been HIPEC, which involves bathing the abdominal cavity in heated chemotherapy immediately after surgery. The idea is to kill microscopic cancer cells that the surgeon could not see or remove.
In advanced ovarian cancer, adding HIPEC to surgical debulking has shown meaningful survival gains. A randomized trial found that median progression-free survival increased from about 11 months with surgery alone to about 14 months with surgery plus HIPEC. Median overall survival improved from roughly 33 months to about 45 months.
14The Lancet Oncology. The Lancet OncologyAnother analysis of locally advanced ovarian cancer found even more dramatic benefits: patients who received HIPEC after surgery were 67% less likely to die from any cause and 75% less likely to die specifically from their cancer compared with patients who had surgery alone.
15PubMed Central. HIPEC as Up-Front Treatment in Locally Advanced Ovarian CancerHIPEC is not universally available and remains a major procedure with its own risks, so it tends to be offered at specialized centers. The peritoneal mesothelioma data mentioned earlier, where five-year survival reached 47% with the combined approach, further supports its role in cancers that coat the omentum and peritoneal lining.
What Chemotherapy Response in the Omentum Tells You
For patients who receive chemotherapy before surgery (neoadjuvant chemotherapy), how well the omental tissue responds to treatment turns out to be a powerful predictor. In one study of ovarian cancer patients treated with chemotherapy followed by delayed surgery, 88% showed visible chemotherapy effects in their omental tissue at the time of surgery. Those who had a good omental response had an estimated median survival of about 84 months, compared with roughly 31 months for those whose omental tissue showed no response. The omental chemotherapy effect was the only factor that independently predicted disease-specific survival.
16PubMed. Omental chemotherapy effects as a prognostic factor in ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulkingThis finding has practical implications. If imaging or surgical exploration shows that the omental disease has shrunk substantially after chemotherapy, it is a strong signal that the tumor biology is favorable and that more aggressive surgery may be worthwhile. Conversely, a non-responding omentum raises concerns about chemoresistant disease.
How Tumor Biology Shapes Outcomes
The pattern of how cancer invades the omentum matters for prognosis, not just whether it gets there. A study examining metastatic high-grade serous carcinoma (the most common aggressive type of ovarian cancer) in the omentum found that the invasion pattern significantly predicted outcomes. Patients whose omental metastases grew in an infiltrating pattern with finger-like projections had uniformly poor outcomes, with all of them either recurring or dying from their disease. By contrast, patients whose tumors grew in a “pushing” pattern, expanding as a cohesive mass, had recurrence or death in only about half of cases.
17PubMed Central. Invasion Patterns of Metastatic Extrauterine High Grade Serous Carcinoma with BRCA Germline Mutation and Correlation with Clinical OutcomesBRCA gene mutations also play a role in the broader landscape of peritoneal cancers. Women who carry BRCA1 mutations face the highest risk of developing peritoneal cancer, with annual incidence rates peaking between ages 60 and 70. Even after preventive removal of the ovaries and fallopian tubes, the risk of peritoneal cancer persists at about 217 per 100,000 per year for BRCA carriers, though this is still far lower than the risk of ovarian cancer would have been without surgery.
18JAMA. Salpingo-oophorectomy and the Risk of Ovarian, Fallopian Tube, and Peritoneal Cancers in Women With a BRCA1 or BRCA2 MutationAmong those who do develop cancer, BRCA2 carriers may have a slight edge. One study noted a non-significant trend toward fewer relapses, longer time to first relapse, and better overall survival in BRCA2 carriers compared with BRCA1 carriers, though the difference did not reach statistical significance.
19International Journal of Gynecological Cancer. Clinicopathologic Characteristics and Survival in BRCA1- and BRCA2-Related Adnexal Cancer: Are They Different?When Colorectal Cancer Involves the Omentum
Omental involvement in colorectal cancer generally signals advanced, widespread disease. A review of patients with metastatic colorectal cancer found that the presence of peritoneal or omental metastases was a significant factor affecting survival. In some series, median survival for patients with omental spread ranged from about 8 to 16 months depending on treatment approach, but multivariate analyses suggested that performance status and the extent of metastatic disease mattered more than whether the primary tumor had been surgically removed.
20Annals of Oncology. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastasesMalignant Ascites and What It Means for Prognosis
When cancer involving the omentum and peritoneum becomes advanced enough, fluid often accumulates in the abdomen, a condition called malignant ascites. This is one of the most challenging complications for patients, causing abdominal distension, difficulty breathing, and poor appetite. Survival after the development of malignant ascites is short, averaging about 20 weeks from diagnosis. While the prognosis at this stage is poor, palliative procedures to drain the fluid can meaningfully improve comfort and quality of life.
21PubMed Central. Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measuresEmerging Approaches Targeting the Omentum
The omentum’s unique immune environment has attracted attention from researchers developing new treatments. Because it contains clusters of immune cells called milky spots, it is both a site where cancer takes hold and a potential launching point for immune-based therapies. Early research has explored delivering engineered viral vectors directly into the peritoneal cavity that specifically target the omentum and stimulate a strong anti-tumor immune response, while keeping systemic toxicity low.
22PubMed Central. The significance of the omentum in locoregional immunotherapy for peritoneal carcinomatosisThis work is still in its early stages, but the concept of using the omentum’s own biology against the cancer growing within it represents a fundamentally different strategy from simply removing the tissue or bathing it in chemotherapy. Whether these approaches will translate into survival improvements remains an open question, but the research is active and the rationale is grounded in the omentum’s distinctive immunological role in the abdomen.